RxDoctor Payments Data

Tolga Icli, MD

Family Medicine · Austintown, OHNPI 1114182979

Payments from drug & device makers

$11,442in general payments, 2019–2025

Across 801 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$982
  • Pfizer$875
  • Amarin Pharma, Inc.$783
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$11,28599%
  • Education$1571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,442 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$140,401
Medicare patients
218
Services billed
1,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban503$179,531
TrulicityDulaglutide77$77,870
OzempicSemaglutide42$66,404
JardianceEmpagliflozin76$36,678
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,714
SynjardyEmpagliflozin/Metformin Hcl32$22,842
JanuviaSitagliptin Phosphate63$22,628
ProliaDenosumab12$20,592
JanumetSitagliptin Phos/Metformin Hcl41$17,654
Janumet XrSitagliptin Phos/Metformin Hcl14$13,893
Tresiba Flextouch U-200Insulin Degludec19$13,388
VascepaIcosapent Ethyl30$13,263
Tresiba Flextouch U-100Insulin Degludec22$12,741
MounjaroTirzepatide37$12,624
Rivastigmine49$12,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$875$179,531503 claims
Lilly USA, LLCTrulicity, Mounjaro$1,029$90,494114 claims
Novo NordiskOzempic$1,439$66,40442 claims
Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat$355$65,441119 claims
MerckJanuvia, Janumet, Janumet Xr$412$54,175118 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$377$39,57378 claims
AmgenProlia$644$20,59212 claims
Otsuka America Pharmaceutical, Inc.Rexulti$106$9,27425 claims
Astellas Pharma US IncMyrbetriq$308$5,07322 claims
AbbVieCombigan$1,579$3,18915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Austintown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →